Literature DB >> 15501781

Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

J Zoe Jordens1, Jeannette N Williams, Graeme R Jones, Myron Christodoulides, John E Heckels.   

Abstract

Understanding the basis of protective immunity is a key requirement for the development of an effective vaccine against infection with Neisseria meningitidis of serogroup B. We have conducted a longitudinal study into the dynamics of meningococcal acquisition and carriage in first-year university students. The detection of carriage of serogroup B meningococci correlated with an increase in detection of serum bactericidal activity (SBA) against both colonizing and heterologous serogroup B strains. Once induced, SBA remained high throughout the study. Although students showed increases in antibodies reactive with capsular polysaccharide and lipopolysaccharide (LPS), these antibody responses were transitory, and their decline was not accompanied by a corresponding decline in SBA. In contrast, there was a significant correlation between the presence of antibodies to the PorA outer membrane protein and SBA against both homologous and heterologous strains. SBA induced by a PorA-negative mutant confirmed the contribution of PorA to heterologous activity. Increases in SBA against a range of serogroup B strains were also observed in students in whom no meningococcal carriage was detected. This heterologous protection could not be associated with the presence of antibodies reacting with capsule, LPS, PorA, PorB, Rmp, Opa, Opc, or pilin, demonstrating that other, as yet unidentified, antigens contribute to the development of immunity to serogroup B meningococci. Identification of such antigens with the ability to induce an effective cross-reactive bactericidal response to a range of strains would be a major step in the production of a universally effective vaccine against infections caused by serogroup B meningococci.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501781      PMCID: PMC523012          DOI: 10.1128/IAI.72.11.6503-6510.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Lack of immunity in university students before an outbreak of serogroup C meningococcal infection.

Authors:  G R Jones; J N Williams; M Christodoulides; K Jolley; J E Heckels
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

2.  Detection of meningococcal carriage by culture and PCR of throat swabs and mouth gargles.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; John E Heckels
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

3.  Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination.

Authors:  D A Ala'Aldeen; K R Neal; K Ait-Tahar; J S Nguyen-Van-Tam; A English; T J Falla; P M Hawkey; R C Slack
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 4.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

5.  Meningococcal carriage in a population of "normal" families.

Authors:  S Greenfield; P R Sheehe; H A Feldman
Journal:  J Infect Dis       Date:  1971-01       Impact factor: 5.226

6.  Meningococcal disease at the University of Southampton: outbreak investigation.

Authors:  A Gilmore; G Jones; M Barker; N Soltanpoor; J M Stuart
Journal:  Epidemiol Infect       Date:  1999-10       Impact factor: 2.451

Review 7.  Neisseria meningitidis serogroup B: laboratory correlates of protection.

Authors:  Clementien Vermont; Germie van den Dobbelsteen
Journal:  FEMS Immunol Med Microbiol       Date:  2002-10-11

8.  Evaluation of the Applied Biosystems automated Taqman polymerase chain reaction system for the detection of meningococcal DNA.

Authors:  M Guiver; R Borrow; J Marsh; S J Gray; E B Kaczmarski; D Howells; P Boseley; A J Fox
Journal:  FEMS Immunol Med Microbiol       Date:  2000-06

9.  Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR.

Authors:  C E Corless; M Guiver; R Borrow; V Edwards-Jones; A J Fox; E B Kaczmarski
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more
  20 in total

1.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

Review 2.  Biofilm formation by the human pathogen Neisseria meningitidis.

Authors:  Martin Lappann; Ulrich Vogel
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

3.  Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort.

Authors:  Fadil A Bidmos; Keith R Neal; Neil J Oldfield; David P J Turner; Dlawer A A Ala'Aldeen; Christopher D Bayliss
Journal:  J Clin Microbiol       Date:  2010-12-01       Impact factor: 5.948

4.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

5.  Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.

Authors:  Mohamed Alamro; Fadil A Bidmos; Hannah Chan; Neil J Oldfield; Emma Newton; Xilian Bai; Jack Aidley; Rory Care; Claire Mattick; David P J Turner; Keith R Neal; Dlawer A A Ala'aldeen; Ian Feavers; Ray Borrow; Christopher D Bayliss
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

7.  The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection.

Authors:  John E Heckels; Jeannette N Williams
Journal:  Genome Med       Date:  2010-07-22       Impact factor: 11.117

8.  Neisseria meningitidis escape from the bactericidal activity of a monoclonal antibody is mediated by phase variation of lgtG and enhanced by a mutator phenotype.

Authors:  Christopher D Bayliss; J Claire Hoe; Katherine Makepeace; Patricia Martin; Derek W Hood; E Richard Moxon
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

9.  A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.

Authors:  Delin Zhu; Jeannette N Williams; Jason Rice; Freda K Stevenson; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

10.  Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Berhanu Melak; Degu Berhanu; Morten Harboe; Jan Kolberg; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2008-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.